Mivelsiran: cAPPricorn-1 Study
Mivelsiran: cAPPricorn-1 Study
Mivelsiran: cAPPricorn-1 Study
The safety and efficacy of mivelsiran are currently being investigated in clinical studies and have not been evaluated by the FDA or any health authority.
If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.
Summary
Mivelsiran targets intracellular and extracellular APP production in the CNS, upstream of amyloidogenic processing, through reduction of APP mRNA. The investigational hypothesis for mivelsiran suggests that the reduction of APP production causes the downstream Aβ protein species to be reduced. This downstream effect may thereby reduce amyloidogenic protein fragments and amyloid deposition in cerebral blood vessels.1 The efficacy, safety, tolerability, and PD of mivelsiran in patients with sporadic or hereditary CAA are being evaluated in an ongoing, global, randomized, double-blind, placebo-controlled, phase 2 study (NCT06393712).2 |
Abbreviations
Aβ = amyloid beta; AD = Alzheimer’s disease; AE = adverse event; APP = Aβ precursor protein; BMI = body mass index; BOLD = blood oxygenation level dependent; CAA = cerebral amyloid angiopathy; CDR = clinical dementia rating; CI = cognitive impairment; CMB = cerebral microbleed; CNS = central nervous system; cSAH = convexity subarachnoid hemorrhage; CSF = cerebral spinal fluid; cSS = cortical superficial siderosis; EOAD = early onset Alzheimer's disease; eGFR = estimated glomerular filtration rate; ICH = clinical intracerebral hemorrhage; IQR = interquartile range; IT = intrathecal; MMSE = Mini‑Mental State Examination; MRI = magnetic resonance imaging; mRNA = messenger ribonucleic acid; OLE = open‑label extension; PD = pharmacodynamics; R = randomization; RNAi = ribonucleic acid interference; sAPPα = soluble amyloid precursor protein alpha; sAPPβ = amyloid precursor protein beta; SD = standard deviation; ULN = upper limit of normal
Study Design – Patient Demographics & Baseline Characteristics – References
The cAPPricorn-1 study is an ongoing, global, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the efficacy, safety, tolerability, and PD of mivelsiran in patients with sporadic or Dutch-type CAA. Enrolled patients will be randomized to receive intrathecal injections of mivelsiran or placebo during the 24-month double-blind treatment period, followed by an optional 18‑month OLE period. The estimated duration of study participation, inclusive of the 60‑day screening period, the double-blind treatment period, the optional OLE, and the 6‑month additional safety follow‑up, is up to 50 months (Figure 1).1,2
Figure 1. cAPPricorn-1 Study Design.1
Abbreviations: CAA = cerebral amyloid angiopathy; IT = intrathecal; R = randomization.
aSporadic and Dutch-type CAA cohorts will be analyzed separately.
From Lee et al.1
The primary endpoint is the annualized rate of new lobar CMBs on brain MRI in patients with sporadic CAA.1
Secondary endpoints include1,2:
Global rank based on severity, count, symptom burden, and timing of new clinical hemorrhagic events and hemorrhagic lesions on brain MRI
Change from baseline in the total CAA small vessel disease score on brain MRI
Incidence of new cerebral hemorrhagic lesions
Assessment of vascular physiology through the change from baseline in cerebrovascular vasoreactivity on BOLD-fMRI
Assessment of non-hemorrhagic disease progression through the incidence of white matter hyperintensities assessed on brain MRI
Pharmacodynamic evaluation of the change from baseline in CSF sAPPα and sAPPβ concentrations
Safety will be assessed by the frequency of AEs in the double-blind treatment period and OLE for up to 48 months.1
Select study inclusion criteria include1:
Able to complete MRI and tolerate lumbar puncture
BMI ≥18 and ≤34 kg/m2
Supportive psychosocial circumstances
Sporadic CAA patients: ≥50 years with a probable CAA diagnosis per the Boston criteria version 2.0 with adaptations
Dutch-type CAA patients: ≥30 years with a known E693Q APP gene variant
Select study exclusion criteria include1:
Moderate or severe AD (CDR global score 2.0 or 3.0) or severe CI (MMSE <22)
History of previous ICH with onset <90 days prior to randomization
Any treatment with amyloid-targeting antibody
Patient Demographics & Baseline Characteristics
Sporadic CAA Cohort
In the sporadic CAA cohort, a total of 170 patients were randomized and 168 patients received treatment (Table 1).3
Table 1. Baseline Characteristics of the Sporadic CAA Cohort in cAPPricorn-1.3
Characteristic | Sporadic CAA Cohort (N=168) |
Age at informed consent, years, mean (SD) | 71.8 (6.3) |
Sex, male, n (%) | 107 (63.7) |
Race, n (%)a |
|
Asian | 1 (0.6) |
Black or African American | 3 (1.8) |
White | 160 (95.2) |
Ethnicity, n (%)a |
|
Hispanic or Latino | 2 (1.2) |
Not Hispanic or Latino | 162 (96.4) |
Comorbidities, n (%) |
|
Hypertension | 111 (66.1) |
Hyperlipidemia/dyslipidemia | 96 (57.1) |
Coronary artery diseaseb | 19 (11.3) |
Atrial fibrillation/atrial flutter | 14 (8.3) |
Diabetes | 11 (6.5) |
Receiving acetylsalicylic acid, n (%) | 25 (14.9) |
Systolic/diastolic blood pressure, mmHg, mean (SD) | 127.7 (13.4) / 73.7 (7.9) |
Prior History of CAA-related clinically symptomatic hemorrhagic stroke,c n (%) | 93 (55.4) |
Primary, non-traumatic ICH, n (%)d | 84 (50.0) |
Acute cSAH, n (%)d | 28 (16.7) |
Transient focal neurological episodes,e n (%) | 48 (28.6) |
Cognitive impairment or dementia,e n (%) | 123 (73.2) |
CDR Global Score, n (%)f |
|
0 | 39 (23.4) |
0.5 | 111 (66.5) |
1 | 17 (10.2) |
MMSE score, median (IQR) | 28.0 (25.5–29.0) |
Abbreviations: CAA = cerebral amyloid angiopathy; CDR = Clinical Dementia Rating; cSAH = convexity subarachnoid hemorrhage; ICH = intracerebral hemorrhage; IQR = interquartile range; MMSE = Mini-Mental State Examination; SD = standard deviation.
aMissing, not reported, or other n=4 (2.4%).
bDefined as medical history of coronary artery disease, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting.
cRepresents participants with symptomatic lobar ICH and symptomatic acute convexity subarachnoid hemorrhage.
dSome participants had both primary, non-traumatic ICH and acute cSAH.
eAcute transient focal neurological episodes and cognitive impairment/dementia are not mutually exclusive.
fn=167.
Imaging Parameters
In the sporadic CAA cohort, the baseline median (IQR) number of lobar CMBs was 40.5 (16.0-121.0). Out of the 168 patients, 26 patients had ≤9 lobar CMBs, 48 patients had 10-30 lobar CMBs, and 94 patients had ≥31 lobar CMBs at randomization.3
The baseline median (IQR) number of cSS foci was 2.0 (0.0-5.5). Out of the 168 patients, a total of 45 patients, 17 patients, 34 patients, 16 patients, and 56 patients had a multifocality rating score of 0, 1, 2, 3, and 4, respectively.3
Updated 06 October 2026
|
|
|
MED-ALL-APP-2400057 3.0 Approved through Oct 2028 |
